The landscape of biotechnology has reached a historic milestone with the FDA approval of Zanvastro, the first-ever therapy for Alexander disease. This ultra-rare neurological condition, characterized by progressive muscle weakness and cognitive decline, has long been a mountain that researchers
California stands at the precipice of a seismic shift in public health that threatens to dismantle the very foundations of the state’s healthcare safety net within the next few years. As 2026 unfolds, the golden state is grappling with a staggering reversal in medical accessibility that experts d
The dismissal of traditional advisory bodies in 2025 necessitated a new level of transparency and cooperation between independent scientific entities. This shift transformed the landscape of public health, moving away from centralized bureaucratic approvals toward a more dynamic, peer-reviewed
The FDA is now implementing a comprehensive strategy to expand its inspectional reach across foreign clinical trial sites to address persistent Good Clinical Practice shortcomings. This pivot marks a significant departure from traditional, domestic-centric monitoring toward a more integrated global
As the healthcare landscape continues to shift toward personalized medicine, the urgency of addressing gender disparities in cardiovascular care has never been more apparent. Heart disease remains the primary cause of mortality for women in the United States, yet the medical community is still
Building a world-class medical institution requires more than just clinical excellence; it demands a radical reimagining of how a hospital serves its community. Professor Timothy J. Eberlein, a titan in surgical leadership and the architect of the Siteman Cancer Center’s meteoric rise, has spent d
